Cancer gene therapy market size was valued at USD 629 million in the year 2020 and is anticipated to reach 3351.79 million at a CAGR of 27% by 2027 during the forecast period 2021-2027. Cancer gene therapy is a process that treats cancers by inserting therapeutic DNA into the patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of the gene. A new technique that is being introduced to cancer gene therapy market involves insertion of new genes into the body that would help to fight against tumor cells. In July 2017, Novartis received U.S. FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK. In June 2013, BioSante Pharmaceuticals, Inc. completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company, ANI Pharmaceuticals, Inc.
Cancer gene therapy market report gives comprehensive outlook on global market scenario, growth trends, shares, with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The report on cancer gene therapy market gives historical, current, and future market sizes (US$ Mn) on the basis of type, therapy, end-user, and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyze the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include manufacturers, distributors, policy makers, and service providers engaged in cancer gene therapy